The dawn of the liquid biopsy in the fight against cancer
Academic Article in Scopus
-
- Overview
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
© Domínguez-Vigil et al. Cancer is a molecular disease associated with alterations in the genome, which, thanks to the highly improved sensitivity of mutation detection techniques, can be identified in cell-free DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive alternative to surgical biopsy and has the potential of revealing the molecular signature of tumors to aid in the individualization of treatments. In this review, we focus on cfDNA analysis, its advantages, and clinical applications employing genomic tools (NGS and dPCR) particularly in the field of oncology, and highlight its valuable contributions to early detection, prognosis, and prediction of treatment response.
status
publication date
published in
Identity
Digital Object Identifier (DOI)
Additional Document Info
start page
end page
volume